Ongoing clinical trials of NOX inhibitors include tests with GKT137839, also known as setanaxib, a preferential direct inhibitor of NOX1 and NOX4, in patients with primary biliary cholangitis and idiopathic pulmonary fibrosis (NCT05014672 and NTC03865927, respectively). Here, NOX4 is linked to pulmonary fibrosis.